Identifying pre-osteoarthritis endotypes and mechanisms

Active Grant Awarded

Award ID
R56AR075356
Recipient
Awarding agency
Obligated
$604,389

Award facts

Completion date 19% complete
Place of performance
Roslindale, MA 02131, USA

Award details come from USAspending.gov.

About this award

The National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the Department of Health and Human Services' National Institutes of Health, awarded Grant R56AR075356 to Hebrew Rehabilitation Center, doing business as Hebrew Senior Life, with $604,389 obligated on September 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds a study of pre-radiographic osteoarthritis (pre-OA), the symptomatic stage that precedes structural joint disease, to identify disease subtypes and molecular precursors. The project applies DNA methylation and proteomics biomarkers to test whether pre-OA reveals subtype-specific mechanisms and systemic effects of OA. Preliminary data include an epigenome-wide association study of 166 pre-OA and 205 knee OA participants. The project will leverage data from the Multicenter Osteoarthritis Study (MOST), a deeply phenotyped longitudinal study of OA that enrolled 1,525 participants. The period of performance runs from the award date to an ultimate completion date of August 31, 2027. Place of performance is Roslindale, MA 02131.

Description

Abstract
There are few effective treatments for OA, and none proven to relieve pain and delay structural joint deterioration. MOST OA studies to date have focused on advanced or end-stage disease where irreversible damage has already occurred. As in other chronic diseases of aging, like alzheimer's disease, there is a need to study individuals before disease onset to identify molecular precursors, which may be more readily targeted and treated. Emerging evidence suggests that OA may be composed of various subtypes, each with different etiologic mechanisms but a final common phenotype, which is often far advanced structurally at the time of clinical presentation. OA is also associated with several CO-morbidities and may increase the risk of cardiovascular disease and cognitive decline. We hypothesize that pre-radiographic OA (pre-OA), a symptomatic stage that precedes development of structural disease, is an important window of opportunity that will provide insights into disease subtypes and the systemic effects of OA. The application of bioparameters like methylation and proteomics may be critical to understanding disease etiology. We have shown that knee, hand, and multi-joint OA are each characterized by a distinct set of DNA methylation markers in blood. However, we found no association between epigenetic aging clocks and OA, suggesting there may be other systemic mechanisms underlying OA. We demonstrate in the preliminary data that in an epigenome-wide association study of 166 pre-OA VS. 205 knee OA participants, top findings are enriched for pathways that were not represented in our previous analyses of knee, hand, and multi- joint OA, and have the potential to differentiate pre-OA from established OA. We will leverage data from the multicenter osteoarthritis study (MOST), a deeply phenotyped longitudinal study of OA that enrolled 1,525 participants with no to little OA and/or pain, providing a window into the earliest stages of OA. A subset of 418 participants meets our definition at baseline and have stored biospecimens and longitudinal data. In aim 1, we will measure DNA methylation and proteomics and use these data to identify pre-OA endotypes (molecular subtypes). In aim 2, we will leverage the deep phenotyping available to identify endophenotypes (clinical subtypes) that capture the molecular underpinnings of disease, then determine their associations with longitudinal OA outcomes. In aim 3, we will link what is happening in the joint to what is happening in the systemic circulation by conducting EX vivo experiments to test the effect of pre-OA (and OA) synovial fluid on changes in blood DNA methylation, and demonstrate that pre-OA (and OA) protein correlates may have effects on cardiovascular disease and cognition in independent data from the framingham heart study. Pre-OA represents a window of opportunity for intervention that, if targeted appropriately, will be key to reducing the burden of OA and other CO-morbidities in older individuals. In this application, we will identify which pathways and measures to target and/or monitor in pre-OA patients, filling a major GAP in the field. This will provide a new paradigm for prevention and treatment of OA and its CO-morbidities.

Quick answers

Who received award R56AR075356?

R56AR075356 was awarded to Hebrew Rehabilitation Center by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 17, 2026.

How much is award R56AR075356 worth?

$604,389 has been obligated on R56AR075356.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award